Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/29/2014)... YORK , Aug. 29, 2014 Pomerantz ... TMS S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ... filed in United States District Court, Southern District of ... 14-cv-6069, is on behalf of a class consisting of ... February 1, 2013 and July 30, 2014, inclusive (the ...
(Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2
... Digital Assent, provider of the award-winning PatientPad® self-service ... that it has appointed Frank Garland as vice president ... Garland will focus on increasing the digital advertising and ... the company,s New York sales office. "Frank ...
... Oct. 20, 2011 Bend Research Inc. ( www.bendresearch.com ... has announced that John McLeod has joined the company ... http://photos.prnewswire.com/prnh/20111020/CL87178 ) McLeod was formerly Director ... six years, where his strategic vision is credited with ...
Cached Medicine Technology:Digital Assent Names Frank Garland Vice President of Advertising Sales 2Bend Research Announces New Chief Financial Officer 2
(Date:9/1/2014)... is a leading review website in the world. It ... announced that GreenGeeks, Arvixe and Hostgator are the best ... http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ) is one of the best web hosting ... of useful products for sale. On its website, customers ... , As one of the Top 10 Web Hosting ...
(Date:9/1/2014)... Television shows filled with action and sound may be ... cookies, carrots and grapes while watching an excerpt from ... program. , , Television has been blamed for helping ... lifestyle. But the focus of why has been on ... other distracting activities that can cause people to eat ...
(Date:9/1/2014)... News) -- You may be able to convince your brain ... suggests. The study included eight overweight and obese people ... to change how people react to different foods. These participants ... obese people who weren,t in the program. Both groups ... and again six months later. The scans revealed that the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 An operating ... a hospital for performing surgical operations. An operating room ... tables, surgical booms, operating room lights, imaging displays as ... a report by Transparency Market Research, a U.S.-based market ... to reach USD 4.5 billion by 2019. , ...
(Date:9/1/2014)... Dennis Thompson HealthDay ... An experimental Ebola drug previously given to two American aid ... deadly virus in laboratory tests, researchers report. The drug, ... even if they didn,t get the medication until five days ... of Ebola who were days or even hours away from ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... to develop the colorectal polyps that can precede colon cancer. ... patients attending for colonoscopy. They found the incidence of polyps// ... cancer - to be greater among current smokers than in ... likely to have more than two polyps, growths greater than ...
... of the antioxidant vitamin E may assist in reducing ... Health Study and the Health Professionals Follow-Up Study', presented by ... Parkinson's disease. The participants have been followed up for several ... ,Those with a high intake of vitamin E ...
... UK inserting a coil into a weakened blood vessel offers ... rate from subarachnoid haemorrhage// - caused by a bursting of ... to 40 per cent in the first 24 hours after ... a clip to prevent further rupture of the blood vessel. ...
... medical centers hope to arbitrate whether a laser can stop ... two forms of macular degeneration, wet and dry. //The dry ... by the formation of yellowish deposits within the layers of ... have a gradual loss of vision. While there are a ...
... researchers of University of Kansas it is observed that poorly ... pain, gas and diarrhea.// Often people suffer from bowel symptoms ... can be found. They have found out that a high ... to digest fructose. ,Found in honey, fruits and ...
... that endometriosis is linked to infertility. There has long ... shows one of the reasons why the disease may ... patients, but concluded that endometriosis causes a certain action ... fluid located near the fallopian tubes. They then studied ...
Cached Medicine News:
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
Medicine Products: